StocksFundsScreenerSectorsWatchlists
MCRB

MCRB - Seres Therapeutics Inc Stock Price, Fair Value and News

0.78USD0.00 (0.00%)Delayed as of 28 Mar 2024, 12:04 pm ET

Market Summary

MCRB
USD0.780.00
Delayedas of 28 Mar 2024, 12:04 pm
0.00%

MCRB Stock Price

View Fullscreen

MCRB RSI Chart

MCRB Valuation

Market Cap

117.8M

Price/Earnings (Trailing)

-1.04

Price/Sales (Trailing)

0.92

Price/Free Cashflow

-0.94

MCRB Price/Sales (Trailing)

MCRB Profitability

Return on Equity

253.53%

Return on Assets

-31.71%

Free Cashflow Yield

-106.4%

MCRB Fundamentals

MCRB Revenue

Revenue (TTM)

127.8M

Rev. Growth (Yr)

-93.44%

Rev. Growth (Qtr)

-79.35%

MCRB Earnings

Earnings (TTM)

-113.7M

Earnings Growth (Yr)

40.04%

Earnings Growth (Qtr)

13.8%

Breaking Down MCRB Revenue

52 Week Range

0.776.87
(Low)(High)

Last 7 days

-2.5%

Last 30 days

-26.7%

Last 90 days

-39.4%

Trailing 12 Months

-85.0%

How does MCRB drawdown profile look like?

MCRB Financial Health

Current Ratio

1.78

MCRB Investor Care

Shares Dilution (1Y)

19.78%

Diluted EPS (TTM)

-0.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230132.1M131.2M127.8M
2022110.5M76.0M41.6M7.1M
202130.7M30.0M155.3M144.9M
202035.4M28.9M23.3M33.2M
201931.6M39.5M37.5M34.5M
201833.1M34.7M20.7M28.3M
201722.1M22.1M32.1M32.1M
20165.9M11.2M16.5M21.8M
2015000638.0K

Tracking the Latest Insider Buys and Sells of Seres Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 16, 2024
arkowitz david
sold
-4,254
1.08
-3,939
chief financial officer
Feb 16, 2024
shaff eric d.
sold
-12,472
1.08
-11,549
ceo and president
Feb 16, 2024
ege david s.
sold
-5,410
1.08
-5,010
see remarks
Feb 16, 2024
von moltke lisa
sold
-4,752
1.08
-4,400
see remarks
Feb 16, 2024
desrosier thomas
sold
-4,254
1.08
-3,939
chief legal officer and evp
Feb 16, 2024
young teresa l.
sold
-3,643
1.08
-3,374
see remarks
Feb 16, 2024
henn matthew r.
sold
-4,503
1.08
-4,170
see remarks
Feb 15, 2024
henn matthew r.
acquired
-
-
11,250
see remarks
Feb 15, 2024
shaff eric d.
acquired
-
-
31,250
ceo and president
Feb 15, 2024
young teresa l.
acquired
-
-
10,625
see remarks

1–10 of 50

Which funds bought or sold MCRB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-80.67
-3,797
487
-%
Mar 11, 2024
VANGUARD GROUP INC
added
9.65
-4,627,220
8,407,430
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
24.38
-447,641
1,220,410
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
-47,846
67,693
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
9.58
-281,000
510,000
-%
Feb 15, 2024
BARCLAYS PLC
reduced
-70.69
-908,000
189,000
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-83.09
-183,656
20,285
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
887
336,430
406,402
-%
Feb 15, 2024
GTS SECURITIES LLC
sold off
-100
-32,142
-
-%
Feb 15, 2024
Virtus ETF Advisers LLC
sold off
-100
-38,451
-
-%

1–10 of 44

Are Funds Buying or Selling MCRB?

Are funds buying MCRB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MCRB
No. of Funds

Unveiling Seres Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 12, 2024
janus henderson group plc
0.0%
483
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 29, 2024
blackrock inc.
5.7%
7,339,454
SC 13G
Nov 07, 2023
federated hermes, inc.
4.04%
5,175,805
SC 13G/A
May 10, 2023
federated hermes, inc.
9.00%
11,500,520
SC 13G/A
Apr 06, 2023
blackrock inc.
5.0%
6,249,086
SC 13G/A
Feb 10, 2023
janus henderson group plc
9.0%
11,248,292
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
4.89%
6,092,937
SC 13G/A
Feb 03, 2023
blackrock inc.
5.2%
6,458,974
SC 13G

Recent SEC filings of Seres Therapeutics Inc

View All Filings
Date Filed Form Type Document
Mar 27, 2024
3
Insider Trading
Mar 27, 2024
4
Insider Trading
Mar 05, 2024
10-K
Annual Report
Mar 05, 2024
8-K
Current Report
Mar 05, 2024
DEF 14A
DEF 14A
Mar 05, 2024
S-8
Employee Benefits Plan
Feb 26, 2024
8-K
Current Report
Feb 23, 2024
PRE 14A
PRE 14A
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading

Peers (Alternatives to Seres Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Seres Therapeutics Inc News

Latest updates
Defense World • 7 hours ago
Yahoo Finance • 07 Mar 2024 • 08:00 am
Investing.com • 06 Mar 2024 • 08:00 am
Seeking Alpha • 05 Mar 2024 • 08:00 am
InvestorsObserver • 01 Mar 2024 • 08:00 am
CNN • 12 Feb 2024 • 03:40 pm

Seres Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-79.4%64.00310126,4739753,4441,2164,2197,221126,7255,2635,71817,5641,4176,0458,1897,6227,03112,5317,32110,6299,055
Operating Expenses-17.0%39,59047,72376,94969,28262,55164,54157,24456,65358,31853,40541,04435,46231,41226,59027,88126,81424,21423,47931,87432,30031,266
  S&GA Expenses-13.8%17,23419,98928,05122,40418,38420,33518,57120,50619,56317,45111,74110,5957,5516,4916,1385,7825,8975,5747,4957,5337,591
  R&D Expenses-5.0%26,84628,25346,79246,22043,11643,93539,64936,75239,88235,95429,30324,86723,86120,09921,74321,03218,31717,90522,88724,76723,675
Interest Expenses0.4%4,0294,0123,1871,8801,7271,501912738744732696759730719716-----262
Net Income13.8%-41,248-47,85446,552-68,796-60,002-64,735-56,624-50,00168,218-48,330-35,465-18,252-30,280-20,714-19,881-18,778-16,409-10,759-24,333-21,287-21,949
Net Income Margin17.4%-0.89*-1.08*-2.30*-35.09*-5.56*-1.36*-0.79*-0.45*-0.22*-4.42*-3.41*----------
Free Cashflow20.8%-48,376-61,05264,751-56,353-60,829-52,060-69,395-53,441123,650-42,249-30,838----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-2.5%359368406270349312273320355396270306343356101111132124146107120
  Current Assets-18.2%17521425111619524821026330435922525226930873.0081.0010090.0010968.0093.00
    Cash Equivalents-19.9%13617023095.0016321413516118822774.0067.0011620762.0055.0065.0049.0010254.0086.00
  Inventory60.0%30.0019.005.00------------------
  Net PPE-4.7%22.0024.0024.0024.0023.0019.0020.0019.0018.0017.0015.0014.0014.0015.0016.0018.0019.0021.0023.0025.0026.00
Liabilities5.4%403383384318338244250239223221169162168168166172181156164177169
  Current Liabilities24.5%99.0079.0078.0064.0086.0082.0089.0082.0082.0095.0056.0048.0046.0046.0044.0044.0046.0042.0043.0042.0042.00
Shareholder's Equity-Infinity%-44.86-23.00-11.0068.0023.0081.00132176101144175188-------
  Retained Earnings-4.4%-978-936-889-935-864-795-735-670-614-564-632-584-548-530-500-479-459-440-424-413-389
  Additional Paid-In Capital1.2%933922912888875863759752746740734728723718435418411409406344341
Shares Outstanding5.0%13512912812712512392.0092.0092.0092.0092.0092.00---------
Float-------240---1,645---220---132--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations19.8%-47,499-59,25565,984-76,584-52,892-59,582-49,897-66,445-51,863127,742-39,695-29,496-17,927-25,866-25,566-24,251-14,047-18,292-11,788-32,39312,666
  Share Based Compensation-41.4%5,0868,67313,4926,8507,2916,3646,7485,0795,6745,8465,0783,6242,7022,2491,9141,9592,1452,0372,0972,0653,754
Cashflow From Investing51.2%-877-1,79710,5172,7395,92640,13123,39912,97213,18625,11246,528-20,738-75,335-110,64417,6519,4374,653-34,524-341-30617,396
Cashflow From Financing345.5%6,4291,44358,1775,6564,59798,02713026,848-7806095857641,985282,30014,5944,54525,110-11860,75948045.00

MCRB Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Collaboration revenue - related party$ 126,325$ 7,128$ 143,857
Type of Revenue [Extensible List]us-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMember
Grant revenue$ 0$ 0$ 1,070
Total revenue126,3257,128144,927
Operating expenses:   
Research and development expenses145,860172,920141,891
General and administrative expenses87,74479,69469,261
Collaboration (profit) loss sharing - related party7041,004(1,732)
Total operating expenses234,308253,618209,420
Loss from operations(107,983)(246,490)(64,493)
Other (expense) income:   
Interest income7,3013,0582,870
Interest expense(13,176)(6,020)(2,910)
Other income (expense)134(705)(1,045)
Total other (expense) income, net(5,741)(3,667)(1,085)
Net loss$ (113,724)$ (250,157)$ (65,578)
Net loss per share attributable to common stockholders, basic$ (0.89)$ (2.31)$ (0.72)
Net loss per share attributable to common stockholders, diluted$ (0.89)$ (2.31)$ (0.72)
Weighted average common shares outstanding, basic128,003,294108,077,04391,702,866
Weighted average common shares outstanding, diluted128,003,294108,077,04391,702,866
Other comprehensive income (loss):   
Unrealized gain (loss) on investments, net of tax of $0$ 10$ 49$ (12)
Currency translation adjustment2(1)(1)
Total other comprehensive income (loss)1248(13)
Comprehensive loss$ (113,712)$ (250,109)$ (65,591)

MCRB Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 127,965$ 163,030
Short term investments018,311
Collaboration receivable - related party8,6740
Inventories29,6470
Prepaid expenses and other current assets9,12413,423
Total current assets175,410194,764
Property and equipment, net22,45722,985
Operating lease assets109,793110,984
Restricted cash8,1858,185
Restricted investments1,4011,401
Other non-current assets[1]41,35410,465
Total assets358,600348,784
Current liabilities:  
Accounts payable3,64117,440
Accrued expenses and other current liabilities[2]80,61159,840
Operating lease liabilities6,6773,601
Short term portion of note payable, net of discount0456
Deferred income - related party7,7300
Deferred revenue - related party04,259
Total current liabilities98,65985,596
Long term portion of note payable, net of discount101,54450,591
Operating lease liabilities, net of current portion105,715107,942
Deferred revenue, net of current portion - related party95,36492,430
Warrant liability5460
Other long-term liabilities1,6281,442
Total liabilities403,456338,001
Commitments and contingencies (Note 16)
Stockholders (deficit) equity:  
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 202200
Common stock, $0.001 par value; 240,000,000 and 200,000,000 shares authorized at December 31, 2023 and 2022, respectively; 135,041,467 and 125,222,273 shares issued and outstanding at December 31, 2023 and 2022, respectively135125
Additional paid-in capital933,244875,181
Accumulated other comprehensive loss0(12)
Accumulated deficit(978,235)(864,511)
Total stockholders' (deficit) equity(44,856)10,783
Total liabilities and stockholders' equity$ 358,600$ 348,784
[1]Includes $38,877 and $8,828 as of December 31, 2023 and December 31, 2022, respectively, of milestones related to the construction of the Company's dedicated manufacturing suite at BacThera AG, or Bacthera (see Note 16, Commitments and Contingencies). Such amounts will form part of the right-of-use asset upon lease commencement.
[2] Includes related party amounts of $28,053 and $34,770 at December 31, 2023 and December 31, 2022, respectively (see Note 18)
MCRB
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.serestherapeutics.com
 EMPLOYEES431

Seres Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Seres Therapeutics Inc? What does MCRB stand for in stocks?

MCRB is the stock ticker symbol of Seres Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Seres Therapeutics Inc (MCRB)?

As of Wed Mar 27 2024, market cap of Seres Therapeutics Inc is 117.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MCRB stock?

You can check MCRB's fair value in chart for subscribers.

What is the fair value of MCRB stock?

You can check MCRB's fair value in chart for subscribers. The fair value of Seres Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Seres Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MCRB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Seres Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MCRB is over valued or under valued. Whether Seres Therapeutics Inc is cheap or expensive depends on the assumptions which impact Seres Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MCRB.

What is Seres Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, MCRB's PE ratio (Price to Earnings) is -1.04 and Price to Sales (PS) ratio is 0.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MCRB PE ratio will change depending on the future growth rate expectations of investors.